Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation.

Sdelci S, Rendeiro AF, Rathert P, You W, Lin JG, Ringler A, Hofstätter G, Moll HP, Gürtl B, Farlik M, Schick S, Klepsch F, Oldach M, Buphamalai P, Schischlik F, Májek P, Parapatics K, Schmidl C, Schuster M, Penz T, Buckley DL, Hudecz O, Imre R, Wang SY, Maric HM, Kralovics R, Bennett KL, Müller AC, Mechtler K, Menche J, Bradner JE, Winter GE, Klavins K, Casanova E, Bock C, Zuber J, Kubicek S.

Nat Genet. 2019 Jun;51(6):990-998. doi: 10.1038/s41588-019-0413-z. Epub 2019 May 27.

PMID:
31133746
2.

A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, Schirghuber E, Müller AC, Caldera M, Wagner A, Herzog R, Penz T, Schuster M, Boidol B, Dürnberger G, Folkvaljon Y, Stattin P, Ivanov V, Colinge J, Bock C, Kratochwill K, Menche J, Bennett KL, Kubicek S.

Nat Chem Biol. 2017 Jul;13(7):771-778. doi: 10.1038/nchembio.2382. Epub 2017 May 22.

PMID:
28530711
3.

Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.

Sdelci S, Lardeau CH, Tallant C, Klepsch F, Klaiber B, Bennett J, Rathert P, Schuster M, Penz T, Fedorov O, Superti-Furga G, Bock C, Zuber J, Huber KV, Knapp S, Müller S, Kubicek S.

Nat Chem Biol. 2016 Jul;12(7):504-10. doi: 10.1038/nchembio.2080. Epub 2016 May 9.

PMID:
27159579
4.

Targeting a cell state common to triple-negative breast cancers.

Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM.

Mol Syst Biol. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664.

5.

Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors.

Klepsch F, Vasanthanathan P, Ecker GF.

J Chem Inf Model. 2014 Jan 27;54(1):218-29. doi: 10.1021/ci400289j. Epub 2014 Jan 9.

6.

Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein.

Klepsch F, Chiba P, Ecker GF.

PLoS Comput Biol. 2011 May;7(5):e1002036. doi: 10.1371/journal.pcbi.1002036. Epub 2011 May 12.

7.

Random mutagenesis of the prokaryotic peptide transporter YdgR identifies potential periplasmic gating residues.

Malle E, Zhou H, Neuhold J, Spitzenberger B, Klepsch F, Pollak T, Bergner O, Ecker GF, Stolt-Bergner PC.

J Biol Chem. 2011 Jul 1;286(26):23121-31. doi: 10.1074/jbc.M111.239657. Epub 2011 May 10.

8.

Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines.

Jabeen I, Wetwitayaklung P, Klepsch F, Parveen Z, Chiba P, Ecker GF.

Chem Commun (Camb). 2011 Mar 7;47(9):2586-8. doi: 10.1039/c0cc03075a. Epub 2010 Dec 21.

PMID:
21173990
9.

Using structural and mechanistic information to design novel inhibitors/substrates of P-glycoprotein.

Klepsch F, Stockner T, Erker T, Müller M, Chiba P, Ecker GF.

Curr Top Med Chem. 2010;10(17):1769-74. Review.

PMID:
20645918
10.

Impact of the Recent Mouse P-Glycoprotein Structure for Structure-Based Ligand Design.

Klepsch F, Ecker GF.

Mol Inform. 2010 Apr 12;29(4):276-86. doi: 10.1002/minf.201000017. Epub 2010 Apr 20. Review.

11.

Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters.

Klepsch F, Jabeen I, Chiba P, Ecker GF.

Curr Pharm Des. 2010 May;16(15):1742-52. Review.

PMID:
20222855

Supplemental Content

Loading ...
Support Center